Latest Ratios: P/E Ratio -6.6x · EV/EBITDA N/A · ROE -108.0%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $82M | $90M | $80M | $17M | $21M | $74M | $20M | $26M | $35M | — | — |
| Enterprise Value | $75M | $83M | $71M | $7M | $9M | $49M | $12M | $11M | $28M | — | — |
| P/E Ratio → | -6.64 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1945.57 | 2133.59 | 440.99 | — | 156.94 | 129.07 | 54.49 | 110.14 | 70.21 | — | — |
| P/B Ratio | 5.85 | 6.84 | 9.88 | 1.68 | 1.79 | 3.27 | 2.65 | 2.18 | 3.47 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1976.02 | 394.64 | — | 65.76 | 86.00 | 32.14 | 46.91 | 55.20 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 5.0% | — | -23.1% | 34.7% | 17.8% | -89.8% | 100.0% | — | — |
| Operating Margin | -27450.0% | -27450.0% | -5295.6% | — | -9752.2% | -2139.6% | -3059.7% | -4853.4% | -2172.2% | — | — |
| Net Profit Margin | -27235.7% | -27235.7% | -5271.3% | — | -9754.5% | -2134.3% | -3072.9% | -4574.2% | -2060.8% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -108.0% | -108.0% | -103.3% | -80.3% | -76.2% | -81.0% | -115.5% | -98.0% | -101.9% | — | — |
| ROA | -90.1% | -90.1% | -90.2% | -71.4% | -66.8% | -68.3% | -84.9% | -71.9% | -77.4% | -114.5% | -26.5% |
| ROIC | -280.1% | -280.1% | — | — | — | — | — | — | — | — | — |
| ROCE | -104.8% | -104.8% | -101.5% | -79.6% | -75.5% | -79.6% | -111.7% | -96.8% | -95.2% | 324.0% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.03 | 0.04 | 0.01 | 0.01 | 0.06 | 0.03 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.34 | — |
| Net Debt / Equity | — | -0.51 | -1.04 | -1.02 | -1.04 | -1.09 | -1.09 | -1.25 | -0.74 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -0.69 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -421.28 | -398.86 | -127.51 | — | — | — |
Net cash position: cash ($7M) exceeds total debt ($490000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.23 | 3.23 | 7.63 | 10.32 | 9.58 | 8.01 | 4.95 | 3.41 | 6.97 | 6.15 | 0.52 |
| Quick Ratio | 3.23 | 3.23 | 7.63 | 10.32 | 9.58 | 8.01 | 4.95 | 3.41 | 6.90 | 6.15 | 0.52 |
| Cash Ratio | 3.23 | 3.23 | 7.36 | 10.10 | 9.18 | 7.87 | 4.67 | 3.31 | 6.44 | 5.81 | 0.39 |
| Asset Turnover | — | 0.00 | 0.02 | — | 0.01 | 0.02 | 0.04 | 0.01 | 0.04 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 1903.21 | 254.09 | — | 670.07 | 116.98 | 255.00 | 429.96 | 529.25 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $46M | $38M | $29M | $29M | $26M | $18M | $12M | $12M | $12M | $12M |
Clinical milestone funding dependency
Based on reported figures, the company trades at a P/S ratio of 1910.41, a multiple that appears disconnected from fundamental performance and reflects a market pricing the firm as a high-risk binary option on its proprietary oral delivery platform rather than on current operational output.
The extreme P/S multiple suggests that investors are ignoring traditional valuation metrics in favor of potential future licensing or acquisition value. This valuation is highly sensitive to clinical trial outcomes, and the lack of a forward P/E or EV/EBITDA indicates that the market does not yet view the company as a viable, profit-generating entity.
As reported in financial statements, the company's ROIC has consistently remained in deep negative territory, reaching -39.4% in 2026Q1, which indicates that every dollar of invested capital is currently being destroyed rather than compounded through the firm's ongoing clinical development activities.
The persistent decay in ROIC reflects a business model where capital is consumed by R&D without the offsetting benefit of commercial revenue. This trend suggests that the company is failing to generate an economic return on its intellectual property, necessitating a fundamental shift in strategy to achieve positive capital efficiency.
According to recent SEC filings, the current ratio has fluctuated significantly, yet the absolute decline in cash reserves to $7.1 million suggests a vulnerable liquidity position that may struggle to support the high costs of upcoming Phase III clinical trials without immediate external financing.
While the current ratio appears superficially high, it is largely a function of the company's limited operational scale rather than a robust cash cushion. Investors should monitor the burn rate closely, as the current liquidity profile leaves little room for error in the event of clinical delays or unexpected regulatory hurdles.
As indicated by the provided data, the use of net margin or P/E ratios to evaluate this business is fundamentally flawed, as these metrics obscure the reality that the company is in a pre-revenue, cash-burning phase where R&D spend is the primary driver of value.
Analysts often misapply standard profitability ratios to clinical-stage biotechs, which leads to misleading conclusions about operational health. Instead, investors should focus on cash runway and the progress of clinical milestones, as these are the true indicators of the company's survival and potential for future value creation.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ENTX stock.
Entera Bio Ltd.'s current P/E ratio is -6.6x. This places it at the 50th percentile of its historical range.
Entera Bio Ltd.'s return on equity (ROE) is -108.0%. The historical average is -95.5%.
Based on historical data, Entera Bio Ltd. is trading at a P/E of -6.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Entera Bio Ltd. has -27450.0% operating margin.